Evaluation of the feasibility of use of
continuous glucose monitoring
(CGM) in a cancer hospital
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Introduction
Inpatient hyperglycemia is associated with poor clinical outcomes. A basal bolus approach to insulin therapy is recommended in the hospital setting (Galindo, et al.
2020). The current standard is to manage blood glucose based on point of care (POC) glucose testing. Recent articles by Galindo et. al (2020) and Fortmann et. Al
(2020) have shown that of real time continuous glucose monitoring (RT-CGM) can be useful in decreasing lower mean glucose, decreasing percentage of time in
hyperglycemia (>250 mg/dL) and increasing detection of hypoglycemic events.
Recently several studies have been conducted evaluating the accuracy/ reliability of CGM in hospitalized patients in the ICU as well as on the general floors.
However, little is known about the benefits of the use of RT-CGM in patients with type 1 and 2 diabetes and cancer in a hospital setting. Patients with cancer have
several factors that can lead to tremendous variability in glucose including administration of steroids, use of artificial nutrition and change in PO status in response to
cancer treatment. Patients with diabetes and cancer are unique in that they often receive steroids as part of their treatment and those undergoing transplants are
often admitted to the hospital for prolonged periods of time.
Our attempts to obtain glycemic control often involve point of care (POC) blood glucose monitoring (fingersticks) upwards of 4 times a day even with this amount of
testing, it is often hard to detect episodes of hyper/hypoglycemia or to prevent extremely glycemic variability.. For some patients with chemotherapy related
neuropathy, fingerstick glucose monitoring can be extremely painful. And for those with thrombocytopenia—use of the “industrial” lancet often leads to prolonged
bleeding times and severe bruising.
The use of RT-CGM could be useful in improving overall glycemic management among this population. In addition, continuous glucose monitors can alarm if a
patient’s glucose is outside of target range which can allow more real-time glucose management and proactive treatment of hypoglycemia in an asymptomatic
patient.

Objective
To determine the feasibility of RT-CGM use
among hospitalized patients with diabetes and
cancer.

Methodology
We conducted a retrospective chart review of 25
adult patient with either T1 or T2DM admitted to
our institution between 8/2020- 01/2021. Patients
were admitted to the general floor. The patients
utilized either their own CGM device or a device
placed by a member of our diabetes service team.
Patients continued to receive standard of care
POC BG measurements using hospital meter (Nova
Biomedical Stat). Insulin dosing was based on
POC testing.
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Results
Among our population there were 12 females
(48%) and 13 males (52%), average age was
58.04 years. Fifty-two percent of patients had
T1DM (20% with immunotherapy-induced T1DM)
and 48% with T2DM. Average length of stay
(LOS) was 11.68 days.
Forty percent of patients received steroids with
potency ranging from hydrocortisone 25 mg to
dexamethasone 20 mg and 20% had platelet
counts less than 140 K/uL (8% less than 50 K/uL)
and 36% wore Dexcom G6 and 64% FreeStyle
Libre.
Of the patients included melanoma-12%,
leukemia-20%, lymphoma-16%, myeloma-12%, GI
cancers- 24% and other-16%.

Conclusion
In our preliminary review, we noted sensors may be safely utilized in
patients with platelets less than 140 K/uL.
The use of RT-CGM was instrumental in detecting
hyper/hypoglycemia that may have otherwise gone
undetected/undocumented.
The use of CGM (with alarms on) allowed the patient to notify the
nursing staff of episodes of hyper/hypoglycemia.
Among hospitalized patients with cancer we found the Libre and
Dexcom sensors could be utilized without adverse events.
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